PKM2 and ALYREF levels have been associated to poor outcomes in bladder cancer patients, suggesting that ALYREF and its target gene PKM2 might be helpful biomarkers for guiding early bladder cancer diagnosis (Wang et al., 2021). This evidence concerns the gene PKM and urinary bladder cancer.